Posted by AGORACOM-JC
at 4:00 PM on Friday, January 22nd, 2021
Fabled Silver Gold controls 100% of the Santa Maria Gold and Silver property in Mexico. It is a high grade underground mine with a rich mining history and a Silver Equivalent 43-101 with 3.2million ounces Indicated and 1.1m inferred.
Now as far as silver projects go 3.2M ounces isn’t very big but when serial mine finder and industry stalwart Peter Hawley was presented with it in 2016, he came out of retirement saying “it was almost too good to be true” and “this is the one I’ve been looking for.
Santa Maria’s best historical intercept to date, reported 11meters of 1,672 g/t Silver & 3.74 g/t gold and ending in mineralization. Moreover, a 2018 PEA is very supportive at current market prices.
Santa Maria has never been systematically, or explored thoroughly with modern methods, until now. FCO is currently conducting their first drill program to support the 43-101 and expects results to start flowing right into June.
It is definitely in a great “neighbourhood” in the mining friendly jurisdiction of Parral which has produced over 250M oz silver. Moreover, multiple major operators in the vicinity, including three toll mills within a 20 km distance.
Watch this great first of many anticipated interviews with CEO Peter Hawley.
Posted by AGORACOM-JC
at 8:47 AM on Friday, January 22nd, 2021
PyroGenesis (PYR:TSX) recently uplisted to the TSX from the TSX Venture and immediately announced plans to apply for a NASDAQ listing. Then, shareholders of PYR discovered the Company’s stock has now been included by the ARK 3D Printing ETF $PRNT …. so it looks like PYR has started off 2021 right where it left off and we sat down with CEO Peter Pascali to talk about some of the bigger topics on the minds of shareholders.
As always, Peter doesn’t disappoint. Watch this great interview.
Posted by AGORACOM-JC
at 6:53 PM on Thursday, January 21st, 2021
Today’s press release from HPQ might have been a little technical for newcomers but the words from CEO Bernard Tourillon explain exactly how important it was:
“With the Gen1 PUREVAP TM NSiR operational and exceeding expectations from the start, HPQ NANO is uniquely positioned to be at the forefront of low-cost manufacturing of Nano Silicon for batteries and other applications ….. We are very confident that the Silicon materials we are producing, with our expected low-cost scalable processes, will be in high demand by batteries, EV manufacturers and other participants in the ongoing renewable energy revolution.”
Moreover, Tourillon couldn’t help but display his feelings and proclaimed this was going to be a fun year for HPQ.
Posted by AGORACOM-JC
at 6:55 PM on Wednesday, January 20th, 2021
Let us start off by saying this interview may be the best one we’ve done in the last 10 years. Here is why.
When Mountain Valley MD issued this press release today, you wouldn’t be alone if you declared “I really don’t know what that means”. The fact of the matter is that MVMD is a double-edged sword that puts it in a position to quite potentially change the way the world delivers drugs and vaccines via physical transport and into the body of patients who need them most. The flip-side of creating something so cutting edge is that it makes it very difficult to understand for anybody without a Life Sciences PhD.
Fortunately, this is where AGORACOM comes in to bridge the worlds between MVMD and the investment community. To do that, the first thing you have to understand is the following:
MVMD Takes Existing Vaccines and Drugs – And Delivers Them Better. Both Into The Body and By Transportation To The World. Way Better.
For the purposes of introducing you to MVMD, we’ll use vaccines as an example given the state of the world since COVID-19 arrived. Specifically, we’ve all heard more about vaccines in 12 months than we have in the last 12 years. One thing we all know about vaccines is that vaccination is the safest way to protect people against infectious diseases.
BUT
One thing we don’t know or understand about vaccinations is that they are only as good as:
1. The global physical delivery system that actually gets them from the manufacturer to the hands of nurse who injects the vaccine;
2. The delivery system into your body (i.e. injection)
If either parts of these delivery systems are weak, or even fail, a vaccine loses some or even all of its potency – and that’s not good.
This is where MVMD comes in. They don’t make vaccines, drugs or pharmaceuticals.
What they do is make their delivery better. Their physical delivery until their ultimate delivery into your body – and that is very good.
By doing so, they help save lives and they help manufacturers be more profitable – and that is very good for humanity and shareholders.
CAN MVMD CREATE A WORLD WITHOUT POLIO … AND THEN OTHER VIRUSES? THEY JUST MIGHT
With the information above in mind, you can now start to get a sense of the power of this quote from MVMD CEO, Dennis Hancock:
“Using a fraction of the Inactivated Polio Vaccine, applying advanced Quicksome™ thin film inside a vial that can be distributed completely outside of the cold chain, and administering through needleless applications is the formula to help us achieve our vision of a world without Polio“.
If you want to find out what is possible, watch this powerful, eye-opening and sometimes emotional interview with CEO Dennis Hancock and Director of Life Sciences Mike Farber.
Posted by AGORACOM-JC
at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
This model has resulted in the following success:
$5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
9 products currently in the market with an annual estimated peak sales of $40M/year
7 products in the pipeline with an annual estimated peak sales of $45M/year
In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:
$6.9M Bought Deal financing at $1.20/shares
A $1.7M Oversubscribed debenture (non-convertible)
If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.
But then came Redesca. We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH. The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market. If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.
But how does a new product capture that much market share? Glad you asked because we asked CEO Steve Saviuk the same question. Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight.
Saviuk agreed and gave the following reasons:
1. Redesca has an 8-year international track record of safety and efficacy. It is already well known
2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.
Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”
Well there you have it. Valeo is a great story. Watch the video.
HOLD ON. THERE’S MORE … A LOT MORE
In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease. What does this mean?
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
Hesperidin may help against Covid-19 viral replication
Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.
Now you have it. That’s the Valeo story as it applies to just 2 of their amazing products. There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.
If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.
When we look back at 2020 this time next year … what we’ve done is very little in my opinion to date.”
Wait … What?
“This year (2021) will see major growth and expansion …. We’re about to reap the rewards from all the groundwork and that is exciting to me … This will be our biggest year by a country mile”
Given the fact we had to do this interview on a Sunday due to Anson “putting in 100 work weeks” and “18-20 Zoom presentations per day”, as well as, 4 pretty significant press releases in the first 2 weeks of 2021, Anson is living up to his word.
Moreover, in this interview, he shows no hesitation when asked if he still feels the same way about 2021.
Watch this great Sunday morning interview with Loop Insights Founder and CEO, Rob Anson.
Posted by AGORACOM-JC
at 7:00 AM on Monday, January 18th, 2021
FansUnite Entertainment $FANS $FUNFF continues to live up to its name as the “Small Cap iGaming Super Company” by yet again announcing major news.
Specifically, their originally announced $5M financing was upsized to $11,000,000 …. and then upsized AGAIN to $13,400,000. And according to CEO Scott Burton, the demand was much higher but they had to make a decision to cut it off at some point.
This should tell you all you need to know about how much demand there is for this small cap online gambling company, who recently made history by becoming the first EVER dedicated esports sportsbook in the United States, along with partner GameCo.
What we love about the Company is having both B2C (direct gambling customers) and B2B (providing the world’s online casinos with new games and technology).
Moreover, they were granted their all important Malta license recently, are now pursuing the invaluable UK license and finally, appear to be in pole position for anticipated changes to online gambling laws in Canada later in 2021.
Watch this amazing interview with $FANS CEO, Scott Burton
Posted by AGORACOM-JC
at 8:34 PM on Thursday, January 14th, 2021
Datamerex (DM:TSXV) has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker.
The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.
As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution. Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.
Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.
As a result, Datametrex has had its’ best year ever in the first 3 quarters of 2020 as follows:
Record revenue of $7.6 million for the nine-month 2020 period compared to $2.6 in 2019
Record revenue of $4.9 million was generated in Q3
First ever positive EBIDTA quarter
If that wasn’t enough, they started off 2021 by announcing the following:
Sold over 23,000 onsite tests for the film industry at locations in Montreal, Toronto and Vancouver for the months of October through December 2020. This represents approximately $4,000,000 CAD in top-line revenue for Q4
Datametrex Providing COVID-19 Testing for Air Canada Front-Line and Inflight Employees
Binding LOI to acquire 100% of Concierge Medical Consultant Inc. a private telehealth and medical concierge services company currently generating revenue through a direct-to-consumer subscription model
Watch this powerful interview with CEO Marshall Gunter to discuss the year that was … and why he’s so optimistic about 2021.
